JWA
ABCL icon

JFS Wealth Advisors’s AbCellera Biologics ABCL Stock Holding History

JFS Wealth Advisors’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-34,516
Closed -$341K – 1944
2022
Q3 		$341K Hold
34,516
– – 0.04% 171
2022
Q2 		$368K Buy
34,516
+8,452
+32% +$71.6K 0.04% 159
2022
Q1 		$254K Hold
26,064
– – 0.02% 207
2021
Q4 		$373K Buy
+26,064
New +$396K 0.04% 177

Other funds holding ABCL

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $4.26B AUM 5.81% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
FFVM
Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JFS Wealth Advisors's ABCL Position: Q4 2022 in Review

JFS Wealth Advisors sold out of AbCellera Biologics (ABCL) in Q4 2022, closing a stake of 34,516 shares — an estimated $341K sold.

JFS Wealth Advisors first reported a position in ABCL in Q4 2021 and held it in 4 quarters. The position peaked at $373K in Q4 2021. 201 funds tracked by Wall St. Rank hold ABCL as of Q4 2022.

  • JFS Wealth Advisors reported no remaining AbCellera Biologics position as of Q4 2022 after selling out during the quarter.
  • JFS Wealth Advisors sold 34,516 AbCellera Biologics shares in Q4 2022, an estimated $341K.
  • JFS Wealth Advisors first reported a position in AbCellera Biologics in Q4 2021 and held it in 4 quarters.
  • JFS Wealth Advisors's AbCellera Biologics position peaked at $373K in Q4 2021.
  • 201 funds tracked by Wall St. Rank held AbCellera Biologics as of Q4 2022.

Based on JFS Wealth Advisors's 13F filing for Q4 2022, filed 13 Feb 2023.